With newer tools for gene editing, is it time to revisit genetic therapy for cystic fibrosis?
作者信息
Gupta Anuj, Gupta Ankita, Boyd Larissa
机构信息
Barts and the London School of Medicine and Dentistry, Institution address - Garrod Building, Turner Street, Whitechapel, E12AD, United Kingdom.
University of Birmingham, Birmingham Medical school, Edgbaston, B152TT, United Kingdom.
出版信息
Genes Dis. 2020 Jan 22;8(2):168-170. doi: 10.1016/j.gendis.2020.01.002. eCollection 2021 Mar.
Abstract
摘要
相似文献
1
With newer tools for gene editing, is it time to revisit genetic therapy for cystic fibrosis?
Genes Dis. 2020 Jan 22;8(2):168-170. doi: 10.1016/j.gendis.2020.01.002. eCollection 2021 Mar.
2
Delivering on the promise of gene editing for cystic fibrosis.
Genes Dis. 2018 Nov 25;6(2):97-108. doi: 10.1016/j.gendis.2018.11.005. eCollection 2019 Jun.
3
Gene delivery to the lungs: pulmonary gene therapy for cystic fibrosis.
Drug Dev Ind Pharm. 2017 Jul;43(7):1071-1081. doi: 10.1080/03639045.2017.1298122. Epub 2017 Mar 7.
4
Powerful tools for genetic modification: Advances in gene editing.
Pediatr Pulmonol. 2017 Nov;52(S48):S15-S20. doi: 10.1002/ppul.23791. Epub 2017 Sep 27.
5
TALEN-Mediated Gene Targeting for Cystic Fibrosis-Gene Therapy.
Genes (Basel). 2019 Jan 11;10(1):39. doi: 10.3390/genes10010039.
6
Transcriptome Profiling and Molecular Therapeutic Advances in Cystic Fibrosis: Recent Insights.
Genes (Basel). 2019 Feb 26;10(3):180. doi: 10.3390/genes10030180.
7
Innovative Therapies for Cystic Fibrosis: The Road from Treatment to Cure.
Mol Diagn Ther. 2019 Apr;23(2):263-279. doi: 10.1007/s40291-018-0372-6.
8
Cystic fibrosis: current therapeutic targets and future approaches.
J Transl Med. 2017 Apr 27;15(1):84. doi: 10.1186/s12967-017-1193-9.
9
Nanomedicine for Cystic Fibrosis.
SLAS Technol. 2019 Apr;24(2):169-180. doi: 10.1177/2472630318824334. Epub 2019 Feb 1.
10
Fixing stem cells via genome editing: hope for cystic fibrosis?
Regen Med. 2016 Jan;11(1):1-3. doi: 10.2217/rme.15.84. Epub 2015 Dec 18.
本文引用的文献
1
Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements.
Nat Biotechnol. 2018 Sep;36(8):765-771. doi: 10.1038/nbt.4192. Epub 2018 Jul 16.
2
Precision Medicine In Action: The Impact Of Ivacaftor On Cystic Fibrosis-Related Hospitalizations.
Health Aff (Millwood). 2018 May;37(5):773-779. doi: 10.1377/hlthaff.2017.1554.
3
Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data.
J Cyst Fibros. 2018 Mar;17(2):218-227. doi: 10.1016/j.jcf.2017.11.019. Epub 2018 Jan 6.
4
Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.
Expert Rev Clin Pharmacol. 2017 Oct;10(10):1055-1072. doi: 10.1080/17512433.2017.1378094. Epub 2017 Sep 22.
5
Mitochondrial replacement therapy: the UK and US regulatory landscapes.
J Law Biosci. 2016 Nov 22;3(3):726-735. doi: 10.1093/jlb/lsw051. eCollection 2016 Dec.
6
Cystic fibrosis: current therapeutic targets and future approaches.
J Transl Med. 2017 Apr 27;15(1):84. doi: 10.1186/s12967-017-1193-9.
7
Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial.
Lancet Respir Med. 2015 Sep;3(9):684-691. doi: 10.1016/S2213-2600(15)00245-3. Epub 2015 Jul 3.
8
Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry.
Ann Intern Med. 2014 Aug 19;161(4):233-41. doi: 10.7326/M13-0636.
9
Designer babies: choosing our children's genes.
Lancet. 2008 Oct 11;372(9646):1294-5. doi: 10.1016/s0140-6736(08)61538-x.
10
Pathophysiology of cystic fibrosis: implications for critical care nurses.
Crit Care Nurse. 2005 Aug;25(4):46-51.
Zotero 插件